Rat anti Mouse CD105 antibody, clone MJ7/18 recognizes mouse CD105, also known as Endoglin, a cell surface glycoprotein member of the TGF beta receptor complex. CD105 is a homodimer that forms a heteromeric complex with TGF beta receptors I and/or II. The complex binds TGF beta 1 and 3 efficiently, and TGF beta 2 less efficiently. It may also play a role in the binding of endothelial cells to integrins and cytoskeletal organisation. It is involved in cardiovascular development. CD105 is expressed on endothelial cells in all tissues except bone marrow and in also found in stromal cells within the connective tissue of the intestine, stomach and heart. It may be a useful marker for proliferating endothelium in tumours.
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Inflamed mouse skin.
- Approx. Protein Concentrations
- IgG concentration 0.5mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch.
- Entrez Gene
- GO Terms
chronological cell aging
patterning of blood vessels
integral to membrane
transforming growth factor beta receptor signaling pathway
transforming growth factor beta binding
regulation of transforming growth factor beta receptor signaling pathway
protein homodimerization activity
smooth muscle tissue development
venous blood vessel morphogenesis
- For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Applications of CD105 antibody
|Immunohistology - Frozen
|Immunohistology - Paraffin
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Flow Cytometry
- Use 10ul of the suggested working dilution to label 1x106 cells in 100ul.
Copyright © 2020 Bio-Rad Antibodies (formerly AbD Serotec)
Secondary Antibodies Available
Negative Isotype Controls Available
Useful Reagents Available
Application Based External Images
Product Specific References
References for CD105 antibody
Ge, A.Z. & Butcher, E.C. (1994) Cloning and expression of a cDNA encoding mouse endoglin, an endothelial cell TGF-beta ligand.
Gene. 138 (1-2): 201-6.
Hallmann, R. et al. (1995) Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier.
Dev Dyn. 202 (4): 325-32.
Bredow, S. et al. (2000) Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin.
Eur J Cancer. 36 (5): 675-81.
Leguerney, I. et al. (2015) Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin.
Ultrasound Med Biol. 41 (1): 197-207.
Crouch, E.E. et al. (2015) Regional and Stage-Specific Effects of Prospectively Purified Vascular Cells on the Adult V-SVZ Neural Stem Cell Lineage.
J Neurosci. 35 (11): 4528-39.
Işık, S. et al. (2016) Intraperitoneal mesenchymal stem cell administration ameliorates allergic rhinitis in the murine model.
Eur Arch Otorhinolaryngol. Jul 5. [Epub ahead of print]
Winkler, S. et al. (2015) Mouse white adipose tissue-derived mesenchymal stem cells gain pericentral and periportal hepatocyte features after differentiation in vitro, which are preserved in vivo after hepatic transplantation.
Acta Physiol (Oxf). 215 (2): 89-104.